A61K 31/7048, A61K 31/366, A61P 25/28
Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.
Dickey, Chad; Shelton, Lindsey; Blagg, Brian; Koren, John; and Blair, Laura, "Hsp90 activator Aha1 drives production of pathological tau aggregates" (2022). USF Patents. 1293.
University of South Florida